Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

TGF-β R2 kinase inhibitor

DRUG CLASS:

TGF-β R2 kinase inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3
PD-L1 overexpression	Gastric Cancer	PD-L1 overexpression	Gastric Cancer	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3	SHR-1701 Sensitive: C3 – Early Trials SHR-1701 Sensitive : C3
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3
HER-2 negative + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	HER-2 negative + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3
PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	LY2109761 Sensitive: C3 – Early Trials LY2109761 Sensitive : C3	LY2109761 Sensitive: C3 – Early Trials LY2109761 Sensitive : C3
NSD3 overexpression	Breast Cancer	NSD3 overexpression	Breast Cancer	LY2109761 Sensitive: D – Preclinical LY2109761 Sensitive : D	LY2109761 Sensitive: D – Preclinical LY2109761 Sensitive : D